Cyclin-dependent kinase inhibitor R547 effect on peripheral blood mononuclear cells: dose response and time course
Summary:
Analysis of peripheral blood mononuclear cells treated with CDK inhibitor R547 at 2 doses for 2 and 24 hours. R547 exerts an antiproliferative effect on various cell lines. Results compared with those from DU145 (GDS5267) and HCT116 cells (GDS5268) to identify pharmacodynamic biomarkers for R547.
GPL570:
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array
Citation:
Berkofsky-Fessler W, Nguyen TQ, Delmar P, Molnos J et al. Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients. Mol Cancer Ther 2009 Sep;8(9):2517-25. PMID: 19755512
